Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability
Oxytocin
Structural features
SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
Sequence
CYIQNCPLG-NH2
Route of administration
IV, IM
Terminal half-life
1-6min
Protein binding
0.3
Absorption and Bioavailability
Bioavailability is poor, subject-dependent and ranges between 0.007 and 0.07% (CV = 50.0%) with the assumption that the total body clearance is similar after intravenous and sublingual administration.